Table of Contents

company-logo

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Barinthus Biotherapeutics Dividend Announcement

• Barinthus Biotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Barinthus Biotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Barinthus Biotherapeutics Dividend History

Barinthus Biotherapeutics Dividend Yield

Barinthus Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Barinthus Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:

Barinthus Biotherapeutics Financial Ratios

P/E ratio-0.93
PEG ratio-0.01
P/B ratio0.34
ROE-34.39%
Payout ratio0.00%
Current ratio8.93
Quick ratio8.93
Cash Ratio7.04

Barinthus Biotherapeutics Dividend FAQ

Does Barinthus Biotherapeutics stock pay dividends?
Barinthus Biotherapeutics does not currently pay dividends to its shareholders.
Has Barinthus Biotherapeutics ever paid a dividend?
No, Barinthus Biotherapeutics has no a history of paying dividends to its shareholders. Barinthus Biotherapeutics is not known for its dividend payments.
Why doesn't Barinthus Biotherapeutics pay dividends?
There are several potential reasons why Barinthus Biotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Barinthus Biotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Barinthus Biotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Barinthus Biotherapeutics a dividend aristocrat?
Barinthus Biotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Barinthus Biotherapeutics a dividend king?
Barinthus Biotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Barinthus Biotherapeutics a dividend stock?
No, Barinthus Biotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Barinthus Biotherapeutics stocks?
To buy Barinthus Biotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Barinthus Biotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.